NCT03745911 - Paclitaxel and TAK-228 in Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

Metastatic Urothelial Cancer

Interventions

COMBINATION_PRODUCT

Paclitaxel and TAK-228

Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued

Trial Locations (5)

31008

RECRUITING

Clínica Universitaria de Navarra, Pamplona

03203

RECRUITING

Hospital General Universitario de Elche, Elche

08208

RECRUITING

Parc Taulí Hospital Universitario, Sabadell

08003

RECRUITING

Hospital del Mar, Barcelona

08041

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona